Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sight Sciences ( (SGHT) ) is now available.
On August 7, 2025, Sight Sciences reported its financial results for the second quarter of 2025, showing a total revenue of $19.6 million, an 8% decrease from the previous year, primarily due to reduced revenue from its Surgical Glaucoma segment. Despite the decline, the company raised its full-year revenue guidance, reflecting confidence in its market position and ongoing efforts to enhance patient outcomes through innovative technologies.
The most recent analyst rating on (SGHT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
Sight Sciences faces significant challenges with declining revenues and ongoing losses, impacting its valuation and financial performance. Despite strong gross margins and liquidity, the lack of profitability and negative cash flows are major concerns. The earnings call highlighted strategic initiatives and cost management efforts, but external market conditions and reimbursement hurdles remain significant risks.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences, Inc. is an eyecare technology company that focuses on developing and commercializing innovative interventional technologies aimed at transforming care and improving patients’ lives, particularly in the areas of glaucoma and dry eye disease management.
Average Trading Volume: 158,740
Technical Sentiment Signal: Sell
Current Market Cap: $180.4M
See more insights into SGHT stock on TipRanks’ Stock Analysis page.